Back

Apolipoprotein B and reverse remodeling in ischemic heart failure.

29 August 2026 (17:50 - 18:00)
Organised by: Logo
Congress Presentation Part of: Targetting the pathophysiology of HFrEF Heart Failure with Reduced Ejection Fraction (HFrEF) ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Assistant Professor Ioana-Patricia Rodean

Emergency County Hospital of Targu Mures, Targu Mures (Romania)

4 More presentations in this session

Presentation thumbnail
GenePHIT Phase 2 baseline characteristics: a double blind, placebo-controlled trial to assess safety and efficacy of AB-1002 gene therapy in heart failure with reduced ejection fraction
Doctor T. Henry (Cincinnati, US)
Abstract Slides Video
Presentation thumbnail
The mechanical strength of the myocardium in patients with heart failure is primarily determined by the collagen fiber content
Doctor T. Shi (Xi'an, CN)
Abstract Slides Video
Presentation thumbnail
Myocardial scar burden, not mechanical dyssynchrony or strain, dictates recovery potential in HFrEF: a CMR study
Doctor C. Yang (Shanghai, CN)
Abstract Slides
Presentation thumbnail
Impact of age on implementation and tolerability of guideline-directed medical therapy in heart failure with reduced ejection fraction
Mrs M. Wilde (Rotterdam, NL)
Abstract Slides

Access the full session

Session thumbnail
Targetting the pathophysiology of HFrEF
Video

The Event

Event poster

ESC Congress 2026

29 August 2026 17:50 CET
You may be interested in
thumbnail
Congress Presentation
Cardiac reverse remodeling in real life, a therapeuthic objective.
22 May 2023
thumbnail
Congress Presentation
Apolipoprotein B outperforms low density lipoprotein particle number as a marker of cardiovascular risk in the UK biobank
1 September 2025
thumbnail
Congress Presentation
The impact of apolipoprotein B levels on left ventricular ejection fraction in heart failure patients
17 May 2025
thumbnail
Congress Presentation
Risk factors control, remnant cholesterol, recurrent events and risk in patients with coronary heart disease. Our experiences
4 April 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources